These letters are supplied by the CDER Freedom of Information Office and only cover Office of Prescription Drug Promotion’s untitled letters. FDA may have redacted or edited some of the letters to remove confidential information.
Similar Posts
OMUFA Reauthorization: Fiscal Years 2026 – 2030
This page is the main website for information pertaining to OMUFA reauthorization activities, including high level meeting minutes with industry while negotiations are ongoing.FDA-TRACK: Prescription Drug User Fee Act Procedural Goals Summary
FDA-TRACK: Prescription Drug User Fee Act Procedural Goals SummaryFDA/MHRA/Health Canada Symposium: Regulatory perspectives in good clinical practice, bioequivalence and good pharmacovigilance practice – 06/02/2026
This symposium will highlight current and emerging topics of interest to the industry related to good clinical practice, bioequivalence and good pharmacovigilance practice.Beaver Street Fisheries, LLC Recalls Great Value Frozen Raw Shrimp Because of Possible Health Risk
Beaver Street Fisheries, LLC of Jacksonville, FL is voluntarily recalling a limited quantity of Great Value Frozen Raw Shrimp EZ-Peel & Deveined Tail-On 21-25 Per lb as a precautionary measure per the recommended action stated in an FDA advisory statement dated 08/19/25 regarding Cesium-137 (Cs-137)www.usmedschoice.com – 716055 – 10/06/2025
Unapproved New Drugs/MisbrandedDevalingam Mahalingam, M.D., Ph.D. – 721145 – 12/11/2025
Clinical Investigator